3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
11
Urinary Bladder Neoplasms
10
Pancreatic Neoplasms
7
Carcinoma, Merkel Cell
6
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Carcinoma, Transitional Cell
4
Carcinoma, Renal Cell
4
Recurrence
3
Neoplasms
3
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Stomach Neoplasms
2
Lymphoma
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Carcinoma, Squamous Cell
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Turcot syndrome
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Cancer Resectable
1
Non-Muscle Invasive Bladder Neoplasms
1
Nasopharyngeal Neoplasms
1
Multiple Myeloma
1
Microsatellite Instability
1
Interventions
Cyclophosphamide
24
Mycophenolic Acid
15
fludarabine phosphate
14
fludarabine
13
Whole-Body Irradiation
13
Tacrolimus
12
Rituximab
12
Melphalan
12
Filgrastim
11
Cyclosporine
11
Busulfan
11
Radiotherapy
10
Peripheral Blood Stem Cell Transplantation
10
Antilymphocyte Serum
10
Methotrexate
9
Doxorubicin
9
Gemcitabine
8
Etoposide
8
Brentuximab Vedotin
8
Sirolimus
7
pembrolizumab
6
Vinblastine
6
Nivolumab
6
Methylprednisolone
6
Granulocyte Colony-Stimulating Factor
6
Alemtuzumab
6
Dacarbazine
5
Cytarabine
5
Cord Blood Stem Cell Transplantation
5
Carmustine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Hodgkin Disease
×
avelumab
×
Clear all
NCT02603419
2020-04-24
JAVELIN HODGKINS
Pfizer
Phase 1
Terminated
34 enrolled
43 charts